1. USP, USP 30–NF 25, Dissolution <711>, United States Pharmacopeial Convention, Inc., Rockville, MD, 2001, pp. 277–282.
2. W. W. Hauck, T. Foster, E. Sheinin, T. L. Cecil, W. Brown, M. Marques, and R. L. Williams. Oral dosage form performance tests: new dissolution approaches. Pharm. Res 22:182–187 (2005).
3. FDA, Center for Drug Evaluation and Research. Guidance for industry: waiver of in vivo bioavailability and bioequivalence studies for immediate-release solid oral dosage forms based on a biopharmaceutics classification system. (2000). www.fda.gov/cder/guidance/3618fnl.pdf . Accessed October 19, 2007.
4. WHO. 2005. Multisource (generic) pharmaceutical products: guidelines on registration requirements to establish interchangeability. Geneva, Switzerland: WHO. (2005). www.who.int/medicines/services/expertcommittees/pharmprep/QAS04_093Rev4_final.pdf . Accessed October 19, 2007.
5. M. Glasgow, S. Dressman, W. Brown, T. Foster, S. Schuber S, R. G. Manning, S. Z. Wahab, R. L. Williams, and W. W. Hauck W. W. The USP performance verification test, part II: collaborative study of USP’s Lot P Prednisone Tablets. DOI 10.1007/s11095-007-9482-2 (2008).